REGN·HealthcareBUY

Regeneron Pharmaceuticals, Inc.

Gianfranco Cacciola·June 8, 2026

Price Target

$800

Upside

+29.3%

Investment Thesis

A single failed melanoma trial knocked Regeneron down 24%, but Dupixent is growing 33%, the balance sheet holds USD 15.8 billion in net cash, and the stock trades at roughly 14x forward earnings. The market is pricing one setback as if it represents the entire pipeline. Our USD 800 target is conservative relative to the company's own cash flow.

Full Report

The complete report includes a DCF valuation, comparable company analysis, and full investment thesis with risk factors.

Download Full Report (PDF)Download DCF Model

Report Details

AnalystGianfranco Cacciola

PublishedJune 8, 2026

SectorHealthcare

RatingBUY

Price Target$800

Current Price$618.71

For educational purposes only. Not investment advice. Price targets reflect analyst estimates as of the publication date.